EMBL Ventures is an independent venture capital investor that manages two Funds with a total of €68 million capital on behalf of major European institutional and private investors. EMBL Ventures' close relationship with the European Molecular Biology Laboratory (EMBL) and its technology transfer organization EMBL Enterprise Management Technology Transfer GmbH (EMBLEM) allows it to finance disruptive technologies in an entrepreneurial start-up environment, aiming ultimately for a transaction with a partner that is seeking to acquire external product innovation. EMBL Ventures is exclusively focused on life-science investments.

"Dr. Stefan Herr is scientist and manager with a sense for impact and perspectives of new medicines. He carefully analyses products in regard to their efficacy and adverse events, their chances in the market and the feasibility of production. Dr. Herr approached me in a very professional manner for developing a new drug to treat ulcerative colitis. Within just one year, he helped to bring this novel drug to a state where an authority-relevant trial can now be started. He was successful in raising further funds to support this trial."
Prof. Wolfgang Stremmel, MD; University Hospital Heidelberg, Department of Gastroenterology, Founder Lipid Therapeutics, Heidelberg